Uric acid as a potential disease modifier in patients with multiple system atrophy
Identifieur interne : 001488 ( Main/Corpus ); précédent : 001487; suivant : 001489Uric acid as a potential disease modifier in patients with multiple system atrophy
Auteurs : Ji E. Lee ; Sook K. Song ; Young H. Sohn ; Phil Hyu LeeSource :
- Movement Disorders [ 0885-3185 ] ; 2011-07.
English descriptors
- KwdEn :
Abstract
Background:: Recent studies have suggested that mitochondrial dysfunction and oxidative stress play a key role in the pathogenesis of multiple system atrophy. Methods:: We evaluated the influence of serum uric acid levels on disease progression in 52 patients with multiple system atrophy using changes in the annualized Unified Multiple System Atrophy Rating Scale scores. Results:: The mean annualized Unified Multiple System Atrophy Rating Scale changes were significantly lower in patients with the highest uric acid quartile compared with those with the lowest quartile (8.4 ± 5.1 vs 20.2 ± 16.0, P = .038). Serum uric acid levels had a significant negative correlation with the annualized Unified Multiple System Atrophy Rating Scale changes (r = −0.40, P = .004). Multiple linear regression analysis showed that only serum uric acid concentration was significantly correlated with the annualized Unified Multiple System Atrophy Rating Scale changes (β = −2.687, P = .011). Conclusions:: These data suggest that serum uric acid may act as a potential disease modifier in multiple system atrophy. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23556
Links to Exploration step
ISTEX:9FDA783E1D171D8F0B82711CD9D73384D43B8E33Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Uric acid as a potential disease modifier in patients with multiple system atrophy</title><author><name sortKey="Lee, Ji E" sort="Lee, Ji E" uniqKey="Lee J" first="Ji E." last="Lee">Ji E. Lee</name><affiliation><mods:affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Song, Sook K" sort="Song, Sook K" uniqKey="Song S" first="Sook K." last="Song">Sook K. Song</name><affiliation><mods:affiliation>Department of Neurology, Jeju University College of Medicine, Jeju, Korea</mods:affiliation></affiliation></author><author><name sortKey="Sohn, Young H" sort="Sohn, Young H" uniqKey="Sohn Y" first="Young H." last="Sohn">Young H. Sohn</name><affiliation><mods:affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Phil Hyu" sort="Lee, Phil Hyu" uniqKey="Lee P" first="Phil Hyu" last="Lee">Phil Hyu Lee</name><affiliation><mods:affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Severance Biomedical Science Institute, Yonsei University, Seoul, South Korea</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9FDA783E1D171D8F0B82711CD9D73384D43B8E33</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23556</idno><idno type="url">https://api.istex.fr/document/9FDA783E1D171D8F0B82711CD9D73384D43B8E33/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001488</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Uric acid as a potential disease modifier in patients with multiple system atrophy</title><author><name sortKey="Lee, Ji E" sort="Lee, Ji E" uniqKey="Lee J" first="Ji E." last="Lee">Ji E. Lee</name><affiliation><mods:affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Song, Sook K" sort="Song, Sook K" uniqKey="Song S" first="Sook K." last="Song">Sook K. Song</name><affiliation><mods:affiliation>Department of Neurology, Jeju University College of Medicine, Jeju, Korea</mods:affiliation></affiliation></author><author><name sortKey="Sohn, Young H" sort="Sohn, Young H" uniqKey="Sohn Y" first="Young H." last="Sohn">Young H. Sohn</name><affiliation><mods:affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Phil Hyu" sort="Lee, Phil Hyu" uniqKey="Lee P" first="Phil Hyu" last="Lee">Phil Hyu Lee</name><affiliation><mods:affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Severance Biomedical Science Institute, Yonsei University, Seoul, South Korea</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-07">2011-07</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1533">1533</biblScope><biblScope unit="page" to="1536">1536</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9FDA783E1D171D8F0B82711CD9D73384D43B8E33</idno><idno type="DOI">10.1002/mds.23556</idno><idno type="ArticleID">MDS23556</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>multiple system atrophy</term><term>progression</term><term>uric acid</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background:: Recent studies have suggested that mitochondrial dysfunction and oxidative stress play a key role in the pathogenesis of multiple system atrophy. Methods:: We evaluated the influence of serum uric acid levels on disease progression in 52 patients with multiple system atrophy using changes in the annualized Unified Multiple System Atrophy Rating Scale scores. Results:: The mean annualized Unified Multiple System Atrophy Rating Scale changes were significantly lower in patients with the highest uric acid quartile compared with those with the lowest quartile (8.4 ± 5.1 vs 20.2 ± 16.0, P = .038). Serum uric acid levels had a significant negative correlation with the annualized Unified Multiple System Atrophy Rating Scale changes (r = −0.40, P = .004). Multiple linear regression analysis showed that only serum uric acid concentration was significantly correlated with the annualized Unified Multiple System Atrophy Rating Scale changes (β = −2.687, P = .011). Conclusions:: These data suggest that serum uric acid may act as a potential disease modifier in multiple system atrophy. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ji E. Lee MD,</name><affiliations><json:string>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Sook K. Song MD</name><affiliations><json:string>Department of Neurology, Jeju University College of Medicine, Jeju, Korea</json:string></affiliations></json:item><json:item><name>Young H. Sohn MD, PhD</name><affiliations><json:string>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Phil Hyu Lee MD, PhD</name><affiliations><json:string>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</json:string><json:string>Severance Biomedical Science Institute, Yonsei University, Seoul, South Korea</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>uric acid</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>multiple system atrophy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>progression</value></json:item></subject><articleId><json:string>MDS23556</json:string></articleId><language><json:string>eng</json:string></language><abstract>Background:: Recent studies have suggested that mitochondrial dysfunction and oxidative stress play a key role in the pathogenesis of multiple system atrophy. Methods:: We evaluated the influence of serum uric acid levels on disease progression in 52 patients with multiple system atrophy using changes in the annualized Unified Multiple System Atrophy Rating Scale scores. Results:: The mean annualized Unified Multiple System Atrophy Rating Scale changes were significantly lower in patients with the highest uric acid quartile compared with those with the lowest quartile (8.4 ± 5.1 vs 20.2 ± 16.0, P = .038). Serum uric acid levels had a significant negative correlation with the annualized Unified Multiple System Atrophy Rating Scale changes (r = −0.40, P = .004). Multiple linear regression analysis showed that only serum uric acid concentration was significantly correlated with the annualized Unified Multiple System Atrophy Rating Scale changes (β = −2.687, P = .011). Conclusions:: These data suggest that serum uric acid may act as a potential disease modifier in multiple system atrophy. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>7.064</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1134</abstractCharCount><pdfWordCount>16185</pdfWordCount><pdfCharCount>106799</pdfCharCount><pdfPageCount>27</pdfPageCount><abstractWordCount>172</abstractWordCount></qualityIndicators><title>Uric acid as a potential disease modifier in patients with multiple system atrophy</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>1536</last><first>1533</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23556</json:string></doi><id>9FDA783E1D171D8F0B82711CD9D73384D43B8E33</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9FDA783E1D171D8F0B82711CD9D73384D43B8E33/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9FDA783E1D171D8F0B82711CD9D73384D43B8E33/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9FDA783E1D171D8F0B82711CD9D73384D43B8E33/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Uric acid as a potential disease modifier in patients with multiple system atrophy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Funding agencies: This research was supported by a grant from the Stem Cell Research Center of the 21st Century Frontier Research Program (SC‐4111) funded by the Ministry of Science and Technology, Republic of Korea. Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Uric acid as a potential disease modifier in patients with multiple system atrophy</title><author><persName><forename type="first">Ji E.</forename><surname>Lee</surname></persName><roleName type="degree">MD,</roleName><affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</affiliation></author><author><persName><forename type="first">Sook K.</forename><surname>Song</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Jeju University College of Medicine, Jeju, Korea</affiliation></author><author><persName><forename type="first">Young H.</forename><surname>Sohn</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</affiliation></author><author><persName><forename type="first">Phil Hyu</forename><surname>Lee</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, Yonsei University Medical College, 250 Seongsanno, Seodaemun‐gu, Seoul 120‐752, South Korea</p></note><affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</affiliation><affiliation>Severance Biomedical Science Institute, Yonsei University, Seoul, South Korea</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-07"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1533">1533</biblScope><biblScope unit="page" to="1536">1536</biblScope></imprint></monogr><idno type="istex">9FDA783E1D171D8F0B82711CD9D73384D43B8E33</idno><idno type="DOI">10.1002/mds.23556</idno><idno type="ArticleID">MDS23556</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background:: Recent studies have suggested that mitochondrial dysfunction and oxidative stress play a key role in the pathogenesis of multiple system atrophy. Methods:: We evaluated the influence of serum uric acid levels on disease progression in 52 patients with multiple system atrophy using changes in the annualized Unified Multiple System Atrophy Rating Scale scores. Results:: The mean annualized Unified Multiple System Atrophy Rating Scale changes were significantly lower in patients with the highest uric acid quartile compared with those with the lowest quartile (8.4 ± 5.1 vs 20.2 ± 16.0, P = .038). Serum uric acid levels had a significant negative correlation with the annualized Unified Multiple System Atrophy Rating Scale changes (r = −0.40, P = .004). Multiple linear regression analysis showed that only serum uric acid concentration was significantly correlated with the annualized Unified Multiple System Atrophy Rating Scale changes (β = −2.687, P = .011). Conclusions:: These data suggest that serum uric acid may act as a potential disease modifier in multiple system atrophy. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>uric acid</term></item><item><term>multiple system atrophy</term></item><item><term>progression</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-09-08">Received</change><change when="2010-11-04">Registration</change><change when="2011-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9FDA783E1D171D8F0B82711CD9D73384D43B8E33/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v26.8</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2011-07">July 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="270" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23556</doi><idGroup><id type="unit" value="MDS23556"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-09-08"></event><event type="manuscriptRevised" date="2010-11-03"></event><event type="manuscriptAccepted" date="2010-11-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2011-12-15"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-05-03"></event><event type="publishedOnlineFinalForm" date="2011-07-21"></event><event type="firstOnline" date="2011-05-03"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1533</numbering><numbering type="pageLast">1536</numbering></numberingGroup><correspondenceTo>Department of Neurology, Yonsei University Medical College, 250 Seongsanno, Seodaemun‐gu, Seoul 120‐752, South Korea</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23556.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="2705"></count></countGroup><titleGroup><title type="main" xml:lang="en">Uric acid as a potential disease modifier in patients with multiple system atrophy<link href="#fn1"></link></title><title type="short" xml:lang="en">Brief Report</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Ji E.</givenNames><familyName>Lee</familyName><degrees>MD,</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Sook K.</givenNames><familyName>Song</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Young H.</givenNames><familyName>Sohn</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af3" corresponding="yes"><personName><givenNames>Phil Hyu</givenNames><familyName>Lee</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>phisland@chol.net</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="KR" type="organization"><unparsedAffiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="KR" type="organization"><unparsedAffiliation>Department of Neurology, Jeju University College of Medicine, Jeju, Korea</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="KR" type="organization"><unparsedAffiliation>Severance Biomedical Science Institute, Yonsei University, Seoul, South Korea</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">uric acid</keyword><keyword xml:id="kwd2">multiple system atrophy</keyword><keyword xml:id="kwd3">progression</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Background:</title><p>Recent studies have suggested that mitochondrial dysfunction and oxidative stress play a key role in the pathogenesis of multiple system atrophy.</p></section><section xml:id="abs1-2"><title type="main">Methods:</title><p>We evaluated the influence of serum uric acid levels on disease progression in 52 patients with multiple system atrophy using changes in the annualized Unified Multiple System Atrophy Rating Scale scores.</p></section><section xml:id="abs1-3"><title type="main">Results:</title><p>The mean annualized Unified Multiple System Atrophy Rating Scale changes were significantly lower in patients with the highest uric acid quartile compared with those with the lowest quartile (8.4 ± 5.1 vs 20.2 ± 16.0, <i>P</i> = .038). Serum uric acid levels had a significant negative correlation with the annualized Unified Multiple System Atrophy Rating Scale changes (<i>r</i> = −0.40, <i>P</i> = .004). Multiple linear regression analysis showed that only serum uric acid concentration was significantly correlated with the annualized Unified Multiple System Atrophy Rating Scale changes (β = −2.687, <i>P</i> = .011).</p></section><section xml:id="abs1-4"><title type="main">Conclusions:</title><p>These data suggest that serum uric acid may act as a potential disease modifier in multiple system atrophy. © 2011 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Funding agencies</b>: This research was supported by a grant from the Stem Cell Research Center of the 21st Century Frontier Research Program (SC‐4111) funded by the Ministry of Science and Technology, Republic of Korea. <b>Relevant conflicts of interest/financial disclosures</b>: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Uric acid as a potential disease modifier in patients with multiple system atrophy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Brief Report</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Uric acid as a potential disease modifier in patients with multiple system atrophy</title></titleInfo><name type="personal"><namePart type="given">Ji E.</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD,</namePart><affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sook K.</namePart><namePart type="family">Song</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Jeju University College of Medicine, Jeju, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Young H.</namePart><namePart type="family">Sohn</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Phil Hyu</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, Korea</affiliation><affiliation>Severance Biomedical Science Institute, Yonsei University, Seoul, South Korea</affiliation><description>Correspondence: Department of Neurology, Yonsei University Medical College, 250 Seongsanno, Seodaemun‐gu, Seoul 120‐752, South Korea</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-07</dateIssued><dateCaptured encoding="w3cdtf">2010-09-08</dateCaptured><dateValid encoding="w3cdtf">2010-11-04</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">17</extent><extent unit="words">2705</extent></physicalDescription><abstract lang="en">Background:: Recent studies have suggested that mitochondrial dysfunction and oxidative stress play a key role in the pathogenesis of multiple system atrophy. Methods:: We evaluated the influence of serum uric acid levels on disease progression in 52 patients with multiple system atrophy using changes in the annualized Unified Multiple System Atrophy Rating Scale scores. Results:: The mean annualized Unified Multiple System Atrophy Rating Scale changes were significantly lower in patients with the highest uric acid quartile compared with those with the lowest quartile (8.4 ± 5.1 vs 20.2 ± 16.0, P = .038). Serum uric acid levels had a significant negative correlation with the annualized Unified Multiple System Atrophy Rating Scale changes (r = −0.40, P = .004). Multiple linear regression analysis showed that only serum uric acid concentration was significantly correlated with the annualized Unified Multiple System Atrophy Rating Scale changes (β = −2.687, P = .011). Conclusions:: These data suggest that serum uric acid may act as a potential disease modifier in multiple system atrophy. © 2011 Movement Disorder Society</abstract><note type="content">*Funding agencies: This research was supported by a grant from the Stem Cell Research Center of the 21st Century Frontier Research Program (SC‐4111) funded by the Ministry of Science and Technology, Republic of Korea. Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>uric acid</topic><topic>multiple system atrophy</topic><topic>progression</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1533</start><end>1536</end><total>4</total></extent></part></relatedItem><identifier type="istex">9FDA783E1D171D8F0B82711CD9D73384D43B8E33</identifier><identifier type="DOI">10.1002/mds.23556</identifier><identifier type="ArticleID">MDS23556</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001488 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001488 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:9FDA783E1D171D8F0B82711CD9D73384D43B8E33
|texte= Uric acid as a potential disease modifier in patients with multiple system atrophy
}}
| This area was generated with Dilib version V0.6.23. |  |